Supplemental Table 2 Patient information, clinical response and urinary MMP levels evaluated in the MFG4991g phase I study

Patient no.

pro MMP-10

(ng/mL)

MMP-1(ng/mL)

MMP-3(ng/mL)

MMP-9(ng/mL)

Best response

Dose (mg/kg)

Tumor originPFS

(Month)

<LOD <LLOQ 0.06 3.97 PD 2 anal 1.4102 <LOD <LOD 0.02 11.43 PD 2 STS 1.5104 <LOD <LLOQ 0.20 1.20 SD 2 thyroid 1.7105 <LOD <LLOQ 0.12 0.09 PD 2 esophageal 1.8

106 <LOD <LLOQ 0.12 4.36 SD 4,8,15,30 bladder cancer 9107 <LOD <LLOQ 0.06 2.35 PD 4 ovarian 1108 <LOD <LLOQ 0.04 0.12 PD 4 adrenal 1.9109 0.05 0.06 0.63 58.58 PD 8 CRC 1.1

110 <LOD 2.74 0.24 1803.63 SD 8 bladder cancer 3.3111 <LOD <LLOQ 0.03 0.18 SD 8 carcinoid 7.3112 <LOD 0.01 0.05 0.22 PD 8 SCCHN 1.3113 0.01 0.00 0.32 0.00 PD 15 CRC 1.1114 0.01 0.02 0.05 223.50 PD 15 CRC 1.2

115 0.01 <LLOQ 0.00 19.03 PD 15mucoepidermo

id 1.6

116 0.01 0.78 1.50 52.35 PD 15 bladder cancer 1.7

117 0.04 1.01 1.18 324.92 PD 15 bladder cancer 0.8

118 0.01 <LLOQ 0.02 2.16 SD 15 adenoid cysitc 12.3119 0.01 <LLOQ 0.01 3.55 SD 30 carcinoid 5.4120 0.01 <LLOQ 0.01 26.70 PD 30 esophageal 1.7

121 0.12 4.37 0.48 418.00 SD 30 bladder cancer 5.8

122 0.09 0.14 0.81 54.26 PD 30 bladder cancer 1.6

123 0.02 0.16 0.12 13.50 PD 30 bladder cancer 0.2

124 0.02 <LLOQ 0.03 0.59 SD 30 adenoid cystic 3.7

125 0.01 <LOD 0.02 0.01 SD 30 bladder cancer 5.7

126 0.12 0.55 0.03 0.33 SD 30 bladder cancer 7.3

127 1.17 7.58 0.18 1.79 PD 30 bladder cancer 0.6

Note: Patients 104 and 118 censored at the last non-PD tumor assessmentAll bladder cancer patients have distant metastatic lesions.